GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB1 day ago · ILMN. BVS. GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...
GSK Announces Positive Topline Data on Co-Administration of
WEB2 days ago · Anti-gE antibody concentrations and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination and met the non-inferiority criteria in the primary endpoint for the humoral immune responses to GSK’s RSV and shingles vaccines. 2 In both groups, the duration of solicited adverse events was short and comparable, and the most ...
GSK Announces Positive Topline Data on Co-Administration of …
WEB3 days ago · PHILADELPHIA, September 18, 2024--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease. Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older.
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US …
WEBFeb 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
WEBJun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to...
- Some results have been removed